- Sionna Therapeutics is advancing two NBD-1 stabilizer compounds for cystic fibrosis, **SION-719** and **SION-451**, after both exceeded PK and exposure targets and were well-tolerated in Phase 1 studies.  **[2036042_tx_380799_0]** **[2036042_tx_380799_6]** 
- **SION-719** will proceed into a Phase IIa proof-of-concept study as an add-on to the standard of care, and **SION-451** has initiated a healthy volunteer dual combination study, with data readouts for both anticipated in **mid-2026**.  **[2036042_tx_380799_0]** **[2036042_tx_380799_1]** **[2036042_tx_380799_7]** **[2036042_tx_380799_8]** 
- The company reported **$337 million** in cash at the end of Q2, providing a cash runway into **2028**, which extends beyond the upcoming key clinical milestones.  **[2036042_tx_380799_1]** 
- Sionna aims to capture market share in the **$11 billion** cystic fibrosis market, projected to grow to **$15 billion** in the next 3-4 years, by offering potentially superior treatment options that drive more patients to normal CFTR function.  **[2036042_tx_380799_0]**

Sionna Therapeutics (SION)